Anthem Blue Cross Connecticut GENE.00059 Hybrid Personalized Molecular Residual Disease Testing for Cancer Form

This document addresses hybrid personalized molecular residual disease (MRD) testing for oncologic disease management. This personalized testing occurs in a two-step process. The first step involves whole exome sequencing (WES) of the tumor tissue. In the second step,  information about the tumor learned from the WES is used to develop a personalized assay to to detect circulating tumor DNA (ctDNA) that assesses MRD. Commercially available personalized MRD tests include the Signatera™ test (Natera Inc., San Carlos, CA) and the RaDaR™ test (Inivata, Research Triangle Park, NC).

Note: Please see the following related documents for additional information:

• CG-GENE-19 Measurable Residual Disease Assessment in Lymphoid Cancers Using Next Generation Sequencing
• GENE.00052 Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling
• GENE.00054 Paired DNA and Messenger RNA (mRNA) Genetic Testing to Detect, Diagnose and Manage Cancer

Position Statement

Investigational and Not Medically Necessary:

Oncologic hybrid personalized molecular residual disease (MRD) tests are considered investigational and not medically necessary for all indications.